Feline Calicivirus Virulent Systemic Disease

Overview and Taxonomy of Feline Calicivirus Virulent Systemic Disease

Feline calicivirus virulent systemic disease (FCV-VSD) represents a dramatic and pathologically distinct manifestation of infection by feline calicivirus (FCV), a highly contagious, single-stranded, positive-sense RNA virus belonging to the family Caliciviridae, genus Vesivirus. While classical FCV infection is typically associated with a mild, self-limiting upper respiratory tract disease (URTD) characterized by oral ulceration, conjunctivitis, and rhinitis, the emergence of highly virulent strains has fundamentally altered the clinical understanding of this pathogen. FCV-VSD, first described in a seminal epizootic in the United States in 1998 involving a novel isolate designated FCV-Ari [16], is a severe, multi-systemic, and frequently fatal condition that has since been documented across North America, Europe, Asia, and Australia [1, 2, 5, 6, 11, 19]. The disease is now recognized as an emerging threat in feline medicine, demanding a comprehensive re-evaluation of viral taxonomy, pathogenesis, and disease management.

The disease presentation of FCV-VSD is starkly divergent from classical FCV. Rather than being confined to the oronasal mucosa, virulent systemic (VS-FCV) strains exhibit a markedly broadened tropism, targeting epithelial and endothelial cells throughout the body, leading to a profound systemic vascular compromise [7, 16]. Clinically, this manifests as a constellation of signs including high fever, profound lethargy, and anorexia, often progressing to severe cutaneous edema, particularly of the face and limbs (pitting edema), and ulcerative dermatitis that can become confluent and necrotic [3, 5, 6]. A hallmark feature is the occurrence of cutaneous ulcers and crusting lesions, often at sites of skin trauma or pressure points. In severe cases, icterus due to hepatic necrosis, epistaxis, and petechial hemorrhages indicative of a hemorrhagic diathesis are observed [16, 22]. The mortality rates reported in outbreaks are exceptionally high, ranging from 33% to 86%, with most studies reporting figures between 39% and 79%, a stark contrast to the negligible mortality of classical URTD [1, 2, 5, 6, 16]. Notably, a significant proportion of affected cats may be previously vaccinated, underscoring the limitation of current vaccines in providing sterilizing immunity against these emergent pathotypes [16, 17].

From a taxonomic perspective, the classification of VS-FCV strains presents a profound scientific challenge and remains a subject of intense investigation. FCV, like all RNA viruses, possesses a high mutation rate due to the error-prone nature of its RNA-dependent RNA polymerase, leading to the existence of a vast array of genetically distinct but antigenically related quasispecies [8, 10]. Critically, no single genetic marker, no specific point mutation, insertion, deletion, or recombination event, has been consistently and unambiguously identified that can definitively discriminate a VS-FCV strain from an avirulent, classical FCV strain [1, 3, 4]. All FCV isolates, regardless of pathotype, are classified into a single serotype, but they are phylogenetically grouped into two major genogroups (GI and GII), with the vast majority of classical and VS-FCV strains clustering within GI, though GII strains are increasingly recognized, particularly in Asia [14, 21, 23]. Within these genogroups, VS-FCV isolates do not form a single, monophyletic clade; instead, they appear interspersed among classical strains in phylogenetic trees, suggesting that the virulent systemic phenotype has arisen independently multiple times, either through convergent evolution or recombination [1, 22].

The molecular basis for the heightened virulence of VS-FCV is an area of active research, with the major capsid protein (VP1) receiving the most scrutiny. The hypervariable region E of the capsid protein is particularly significant as it is responsible for binding to the primary cellular receptor, feline junctional adhesion molecule A (fJAM-A), as well as for interactions with the minor structural protein VP2 necessary for viral entry [7, 20, 21]. An innovative multiple correspondence analysis (MCA) of amino acid properties within region E has recently been shown to statistically differentiate between classical and VSD strains, identifying seven key residue positions that are statistically significant for pathotype differentiation [7]. These residues are predominantly located in the N-terminal portion of region E and are predicted to influence interactions with fJAM-A or VP2, suggesting that post-binding events and specific conformational changes in the capsid may be the mechanistic drivers of the broadened tropism and systemic pathogenesis, rather than mere receptor affinity differences [7]. Mutations at specific sites, such as the NNS motif at residues 441–443 in the E region, have been correlated with disease severity in some studies, where an asparagine at position 442 was found in a pathogenic isolate, while its absence was associated with an attenuated phenotype [24]. However, these correlations are not absolute, and the "VS-FCV" designation remains a phenotypic rather than a genotypic classification.

Adding to the taxonomic complexity, recombination events between co-infecting FCV strains are well-documented and may play a role in the emergence of virulent variants. Intergenic recombination between the p30 coding region and the ORF1/ORF2 junction has been identified in a Korean VS-FCV strain (14Q315) causing hemorrhagic-like disease, with the recombinant region showing high similarity to the highly virulent UTCVM-H1 strain [22]. Furthermore, environmental factors and host immune status can influence the outcome of infection. The majority of VS-FCV outbreaks are epizootic and nosocomial in origin, occurring in shelters, catteries, and veterinary hospitals, where the virus can spread rapidly via fomites and the hands of caregivers [2, 6, 9]. Prolonged viral shedding from recovered animals and the existence of asymptomatic carriers contribute to the maintenance of FCV in multi-cat environments [15, 17]. The universal vaccination of cats with modified-live or inactivated vaccines is imperative (core vaccine per WOAH guidelines), and while these vaccines effectively reduce clinical disease severity and mortality, they do not prevent infection or viral shedding, and their efficacy against a given VS-FCV field strain is unpredictable due to high antigenic drift [12, 13, 17]. The World Health Organization (WHO) recognizes the importance of caliciviruses in animal health, though FCV is not considered a public health threat. The global distribution and high mortality of FCV-VSD necessitate its recognition as a critical emerging disease requiring international surveillance and research coordination [17, 18].

Molecular Pathogenesis and Virulence Determinants of FCV-VSD

The emergence of virulent systemic disease (FCV-VSD) represents a profound shift in the pathobiology of feline calicivirus, transforming a typically self-limiting oronasal pathogen into an agent capable of inducing fulminant multisystemic vasculitis, hepatocellular necrosis, pulmonary oedema, and mortality rates exceeding 70% in epizootic settings [2, 6]. Understanding the molecular underpinnings of this virulence transition is not merely an academic exercise; it is a critical prerequisite for the rational design of antiviral therapeutics, the development of broadly protective vaccines, and the implementation of effective surveillance strategies. The existing literature, drawn from outbreaks across four continents over two decades, reveals a pathogenetic landscape defined not by a single "virulence switch" but by a complex, multifactorial interplay of capsid structure, receptor tropism, host immune subversion, and genomic plasticity.

The Capsid Protein VP1 as the Epicentre of Tropism and Pathogenicity

The major capsid protein VP1, encoded by open reading frame 2 (ORF2), is the primary determinant of FCV cell tropism and the principal target of the host neutralizing antibody response. Extensive structural and functional analyses have focused on the hypervariable E region of VP1, a surface-exposed loop that mediates critical interactions with the cellular receptor, feline junctional adhesion molecule A (fJAM-A), as well as with the minor capsid protein VP2 during viral entry and uncoating [7, 20]. It has been a long-standing hypothesis that specific amino acid signatures within this region could distinguish the VSD pathotype from classical upper respiratory tract disease (URTD) isolates. The search for such markers, however, has been remarkably elusive.

A landmark study employing multiple correspondence analysis (MCA) on a Boolean matrix of physico-chemical amino acid properties, rather than primary sequence alone, was the first to achieve statistically significant differentiation between VSD and classical strains [7]. This analysis identified seven key residues, predominantly located within the N-terminal hypervariable segment of region E. Structural modeling suggested these residues are strategically positioned at the interface with fJAM-A or VP2, implying that post-binding conformational changes or alterations in entry kinetics, rather than simple receptor engagement, may be the critical determinants of the expanded VSD tropism [7]. This finding elegantly explains why earlier, more reductive attempts to find a single "VSD motif" failed. Further structural modeling supports that the VP1 E region is not a static binding domain but a dynamic switch; substitutions in these key residues may influence the pH sensitivity of uncoating or the efficiency of VP2-mediated pore formation in the endosomal membrane, processes that are essential for successful infection of diverse cell types, including endothelial cells and macrophages [20].

Despite this advance, it is crucial to emphasize that no single, universally conserved mutation has been identified across all VSD isolates. A comprehensive analysis of seven specific residues in the hypervariable E region from Australian VSD outbreaks found that their properties could not reliably differentiate between pathotypes [1]. Similarly, Italian VSD strains failed to show consistent amino acid changes relative to reference VS-FCV sequences [3], and a Thai isolate causing a fatal VSD-like syndrome clustered with classical strains in phylogenetic analyses [25]. This has led to a critical conceptual shift: the VSD phenotype is likely not encoded by a fixed set of residues but rather arises from specific combinations of conformational states and kinetic properties conferred by unique constellations of mutations within the E region. Indeed, research on Chinese isolates has pinpointed a motif at positions 441–443 of VP1, noting that the sequence NNS is characteristic of highly virulent strains and was absent from a naturally attenuated isolate (QD-7) [24]. However, this marker, while intriguing, has not yet proven universal across all global VSD strains, suggesting it may be a marker within specific phylogenetic clades rather than a root cause of virulence.

Endothelial Cell Tropism, Vasculitis, and the Dissemination Cascade

The defining clinical and pathological feature that separates VSD from classical FCV is the involvement of the vascular endothelium. While classical FCV is largely restricted to epithelial cells of the oropharynx and respiratory tract, VSD strains exhibit a dramatically expanded tropism, enabling productive infection of endothelial cells throughout the body. This shift is the direct molecular cause of the characteristic cutaneous oedema, ulceration, haemorrhagic diathesis, and multi-organ failure that define the disease.

The process of systemic dissemination can be conceptualized as a cascade. After initial replication in the oropharyngeal epithelium, VSD strains must overcome several barriers to reach the systemic circulation. The ability to infect and replicate within alveolar macrophages appears to be a crucial gateway, providing a protected niche for viral amplification prior to haematogenous spread [4, 10]. Immunohistochemical evidence from a fatal kitten case confirmed that IBA-1-positive alveolar macrophages were the primary viral target cells and pulmonary replication site, with the lung harboring the highest viral RNA load of any organ [4]. This pulmonary phase likely seeds a secondary viraemia that then targets endothelial cells. Productive infection of the endothelium induces a cascade of pro-inflammatory cytokines and chemokines, leading to increased vascular permeability, oedema, and the recruitment of inflammatory cells that exacerbate tissue damage. The resulting vasculitis is not a secondary immune phenomenon but a direct consequence of viral replication within the vessel wall, as demonstrated by the detection of FCV antigen within endothelial cells by immunohistochemistry in both experimental and field cases [11, 16].

The ability to traffic from the respiratory epithelium to the systemic endothelium is not merely a function of capsid sequence alone. The non-structural proteins of FCV, particularly the protease-polymerase (NS6-7) and the helicase (NS3), are increasingly recognized as key players in establishing a cellular environment permissive to systemic spread. These proteins are potent antagonists of the innate immune response, particularly the interferon (IFN) signaling pathway [10, 20]. By suppressing the local IFN-driven antiviral state, VSD strains can replicate to higher titers locally, increasing the probability of encountering and infecting motile macrophages and subsequently breaching the endothelial barrier.

Genetic Plasticity, Recombination, and the Emergence of Virulence

FCV, as a single-stranded positive-sense RNA virus, possesses an RNA-dependent RNA polymerase (RdRp) that is inherently error-prone, lacking proofreading capability. This results in a high mutation rate, generating a swarm of closely related but genetically distinct variants, a quasispecies, within a single host [10, 20]. This quasispecies nature is the engine of FCV evolution. Most mutations are deleterious or neutral, but a small subset can confer a selective advantage, such as the ability to evade pre-existing neutralizing antibodies or to bind to a new receptor, such as that on endothelial cells.

However, mutation alone is not the only driver. The literature provides unequivocal evidence that intergenic recombination is a major force in shaping FCV genomes and potentially in generating VSD strains. A seminal analysis of the Korean strain 14Q315, isolated from a cat with a fatal haemorrhagic-like disease, identified a clear recombination event at the p30-ORF1/ORF2 junction [22]. The non-recombinant portion of the genome was highly similar to Korean and Chinese FCVs, while the recombinant segment shared highest identity with the virulent American strain UTCVM-H1, known to cause haemorrhagic disease. This strongly suggests that a "virulence module" from an imported VSD strain recombined into a local, circulating FCV backbone, creating a novel and lethal chimeric virus [22]. This finding has profound implications: it demonstrates that virulence determinants can be horizontally transferred between strains, and that the emergence of VSD is not a slow, stepwise process but can occur as a sudden, discontinuous event. The geographic isolation of virulent strains on separate continents, such as the emergence of distinct VSD lineages in Australia that evolved seemingly in situ [1], is entirely consistent with local recombination events involving imported or endemic strains.

Host-Pathogen Dynamics: From Immune Subversion to Systemic Collapse

The transition from localized respiratory infection to fatal systemic disease is not solely a function of viral genetics; it is a battle between the virus and the host's immune system, a battle that VSD strains appear to win with devastating efficiency. The virulence of VSD strains is inextricably linked to their capacity to subvert the host's innate and adaptive immune defenses.

First, the ability to infect and replicate in antigen-presenting cells, particularly macrophages and dendritic cells, is a hallmark of highly pathogenic caliciviruses, analogous to rabbit hemorrhagic disease virus (RHDV) [16, 20]. This infection is not merely a passive consequence of expanded tropism; it is an active strategy for immune evasion. By replicating within these cells, VSD strains can impair antigen presentation, disrupt the initiation of an effective adaptive immune response, and turn the key orchestrators of immunity into factories for viral production. This is supported by clinico-pathological observations in VSD outbreaks, which consistently document profound lymphopenia and macrothrombocytopenia [2]. These haematological findings are not simply bystander effects of systemic inflammation but likely reflect direct viral infection or virally-induced destruction of hematopoietic precursors and circulating lymphocytes.

Second, the virus's antagonism of the type I interferon system, mediated by its non-structural proteins, is a critical virulence determinant. While activation of the type I IFN pathway is a cornerstone of the host antiviral response, and is essential for restricting FCV replication in vitro, VSD strains have evolved mechanisms to delay, dampen, or subvert this response long enough to establish a systemic foothold [10, 26]. The dysregulation of this pathway has a profound consequence: it can paradoxically lead to the upregulation of immune checkpoint molecules.

Emerging research into the pathogenesis of feline infectious peritonitis (FIP), another fatal systemic feline coronavirus, has provided a powerful comparative model for FCV-VSD. A seminal study demonstrated that FIP virus (FIPV), but not its benign enteric counterpart (FECV), specifically upregulates PD-L1 (programmed death-ligand 1) on infected macrophages, and that this upregulation is driven by the type I IFN response elicited by the virulent virus [26]. The PD-1/PD-L1 axis is a potent inhibitor of T-cell activation. By inducing PD-L1, FIPV creates an "immune-privileged" sanctuary for infected macrophages, effectively shutting down the cytotoxic T-cell response that is essential for viral clearance. It is highly plausible that VSD strains of FCV employ a similar or identical mechanism. The profound lymphopenia and the observation that vaccinated cats, which have memory T-cell responses, can still succumb to VSD [16] are consistent with a model where the virus actively disarms the cellular immune response. The demonstration that vaccination induces Th1-type cytokine responses and IFN-γ-releasing PBMCs, which are associated with protection against severe disease [12, 13], further underscores that the T-cell response is the critical barrier between containment and systemic dissemination. Bypassing this barrier, either through PD-L1 induction or other immunosuppressive strategies, is likely a defining characteristic of the VSD pathotype.

The Enigma of Host Predisposition and Nosocomial Amplification

The molecular pathogenesis of VSD cannot be divorced from its epidemiological context. A striking feature of VSD outbreaks is their apparent sporadicity and the variability in clinical outcome among exposed cats. Even within a single outbreak, some cats develop fulminant disease while others remain asymptomatic or develop mild signs [6, 11]. This suggests that host factors, including age, co-morbidities, genetics, and vaccinal status, play a permissive role in enabling the virulent phenotype to manifest. The index case in one Italian shelter was an FIV-positive cat, leading to the suggestion that pre-existing immunosuppression may provide a fertile ground for the emergence and selection of more virulent viral variants [11]. Once a VSD strain emerges, its amplification in a high-density, stressed environment such as a shelter or veterinary intensive care unit is catastrophic. The virus exploits fomite transmission (via caregivers' hands, stethoscopes, and contaminated surfaces), and its high-titer shedding from oropharyngeal and cutaneous lesions means that even rigorous disinfection protocols may fail [6, 8]. The documented observation that virulence appeared to increase with serial passage through hospitalized cats during a French outbreak [6] is a sobering reminder that the viral quasispecies can continue to evolve within the outbreak itself, selecting for increasingly aggressive variants that are better adapted to the nosocomial environment and the partially immunized host.

Clinical Epidemiology and Nosocomial Outbreak Dynamics

Feline calicivirus virulent systemic disease (FCV-VSD) represents a paradigmatic shift in our understanding of calicivirus pathogenesis, transitioning from a pathogen historically associated with mild, self-limiting upper respiratory tract disease (URTD) to one capable of inducing a fulminant, multisystemic syndrome with mortality rates rivaling those of the most feared feline infectious diseases. The clinical epidemiology of FCV-VSD is characterized not by endemic stability but by sporadic, explosive epizootics that emerge unpredictably within susceptible populations, often with devastating consequences. Unlike the enzootic circulation of classical FCV strains, which maintain a relatively stable prevalence in multi-cat environments, VS-FCV strains appear to arise de novo from the quasispecies cloud of circulating viruses, a phenomenon driven by the error-prone RNA-dependent RNA polymerase and the immense selective pressures exerted by host immunity and population density [1, 8, 10]. This evolutionary plasticity underpins the most challenging aspect of FCV-VSD epidemiology: the absence of a stable, predictable phylogenetic lineage that can be reliably identified as “virulent.” As multiple independent investigations have confirmed, VS-FCV isolates do not cluster into a single monophyletic clade; rather, they are interspersed among classical strains in phylogenetic reconstructions, and no consistent amino acid signature in the capsid protein has yet been identified that universally distinguishes the two pathotypes [1, 3, 4, 7]. This genetic heterogeneity complicates surveillance efforts and necessitates a syndromic approach to outbreak detection.

The global distribution of FCV-VSD has expanded considerably since the first well-characterized epizootic was described in the United States in 1998, involving the FCV-Ari strain, which caused a hemorrhagic-like fever in a cluster of cats associated with a veterinary practice [16]. Subsequent reports have documented outbreaks across North America, Europe, Asia, and Australia, confirming that no geographic region is exempt [1, 2, 5, 6, 11, 19]. The incidence of recognized outbreaks appears to be increasing, though whether this reflects a true rise in viral emergence or enhanced clinical awareness and diagnostic capability remains a subject of debate. Critically, FCV-VSD is not a disease of unvaccinated, stray, or immunocompromised populations alone. A hallmark of the epidemiology is that outbreaks frequently occur in well-vaccinated, privately owned cats with documented vaccination histories, including those housed in high-biosecurity environments such as referral veterinary hospitals [2, 6, 16]. This observation underscores the failure of current vaccines to provide sterilizing immunity against heterologous VS-FCV strains and highlights the antigenic distance that can exist between vaccine strains (typically FCV-F9 or related isolates) and emergent virulent variants [12, 13, 17, 30]. The ABCD guidelines and multiple field studies have confirmed that while vaccination reduces the severity of clinical signs and viral shedding, it does not prevent infection or the establishment of a carrier state, leaving populations vulnerable to the introduction of novel strains [15, 17, 31].

Nosocomial Outbreak Dynamics: A Detailed Analysis

The most alarming epidemiological feature of FCV-VSD is its propensity for nosocomial transmission within veterinary hospitals, where the convergence of a susceptible, often stressed population, high patient throughput, and potential lapses in infection control creates a perfect storm for explosive amplification. Nosocomial outbreaks have been reported from veterinary teaching hospitals, emergency and critical care units, and general practice settings in the United States, the United Kingdom, France, Korea, Australia, and continental Europe [1, 2, 6, 16]. The dynamics of these outbreaks are remarkably consistent across geographic and temporal boundaries, suggesting a stereotyped pattern of viral spread that can be exploited for early detection and intervention.

The index case in a nosocomial outbreak is frequently a cat admitted for a seemingly unrelated condition, often a routine surgical procedure, such as ovariohysterectomy, or management of a chronic disease, which is incubating FCV-VSD at the time of admission or is asymptomatically shedding a pre-emergent virulent strain [6, 9, 16]. The incubation period, as determined from careful epidemiological tracing in multiple outbreaks, is typically 4 to 5 days, though it can range from 2 to 14 days depending on the viral dose and route of exposure [6, 16]. During this prodromal phase, the cat may exhibit only vague signs of malaise, pyrexia, or anorexia, which are easily attributed to postoperative stress or the primary presenting complaint. This diagnostic ambiguity is a critical vulnerability, as the cat continues to shed high titers of virus into the hospital environment, contaminating surfaces, equipment, and the hands and clothing of veterinary personnel.

Transmission within the hospital is predominantly indirect, via fomites, with the hands of caregivers serving as the primary vector [6]. FCV is a non-enveloped virus with remarkable environmental stability; it can persist on dry surfaces for weeks at room temperature and is resistant to many common disinfectants, including quaternary ammonium compounds and alcohols, unless used at appropriate concentrations and contact times [17]. The virus is shed in extraordinarily high quantities from oropharyngeal secretions, nasal discharge, conjunctival exudate, and, notably, from ulcerated skin lesions, which are a pathognomonic feature of VSD [5, 6, 28]. The presence of cutaneous ulcers at venipuncture sites, surgical incisions, and areas of skin trauma is a particularly sinister hallmark of nosocomial spread, as it indicates that the virus is exploiting breaches in the skin barrier to establish a portal of entry, bypassing the traditional mucosal route [6]. In the French outbreak described by Deschamps et al. (2015), this phenomenon was so pronounced that any cat subjected to a skin-penetrating procedure in the intensive care unit developed a rapidly expanding, necrotizing ulcer at that site within 48–72 hours, serving as an early sentinel of the outbreak [6].

Once established, the outbreak propagates with alarming speed. In the Korean outbreak reported by Park et al. (2024), 18 cats were affected over a six-month period across two distinct waves, with an overall mortality rate of 72.2% [2]. The French outbreak, which occurred in the ICU of a veterinary school hospital, involved 14 cats with a combined mortality (including euthanasia) of 79%, the highest ever reported at the time [6]. The Australian study by Bordicchia et al. (2021) documented three separate outbreaks involving 23 cats, with a mortality rate of 39%, though this lower figure may reflect differences in case definition, treatment intensity, or the inherent virulence of the circulating strains [1]. The mortality in these settings is driven not only by the intrinsic pathogenicity of the virus, which causes severe vasculitis, disseminated intravascular coagulation, hepatic necrosis, and pulmonary edema, but also by the difficult decision to euthanize affected cats to prevent further suffering and halt the chain of transmission [2, 6, 16].

A critical observation from multiple outbreak investigations is the phenomenon of serial passage of virulence. As the virus is transmitted from cat to cat within the hospital environment, it appears to undergo rapid adaptation, with each subsequent passage resulting in a more aggressive clinical phenotype and a shorter incubation period [6]. This is consistent with the quasispecies theory of RNA virus evolution: the immense genetic diversity within the viral population allows for the rapid selection of variants with enhanced replicative fitness, broader tissue tropism, or improved immune evasion capabilities under the selective pressure of a novel host environment. The implication for outbreak management is profound: the window for effective intervention narrows with each passing day, and a delay of even 48 hours in recognizing the outbreak can mean the difference between containment and a full-blown epizootic.

The role of asymptomatic carriers in sustaining nosocomial transmission cannot be overstated. FCV is notorious for establishing persistent infections in the tonsillar crypts and oropharyngeal mucosa of recovered cats, which can shed virus continuously or intermittently for months to years without showing clinical signs [15, 17, 20]. In the shelter environment, carrier rates can exceed 40–50% [14, 15, 31]. When such a carrier is admitted to a hospital for an unrelated procedure, it can serve as an unsuspecting reservoir, seeding the environment with virus and initiating an outbreak. The detection of these carriers is challenging, as routine diagnostic testing is not performed on all admissions, and point-of-care antigen tests lack the sensitivity to detect low-level shedding [27, 32]. Real-time RT-PCR assays targeting conserved regions of the genome, such as the 5′ untranslated region or the ORF1 polymerase gene, offer superior sensitivity and are the gold standard for outbreak investigation, but they are not universally available in practice settings [29, 32].

The economic and operational consequences of a nosocomial FCV-VSD outbreak are devastating. Affected hospitals are typically forced to close for a minimum of two weeks to undergo thorough cleaning and disinfection, with the associated loss of revenue and disruption to patient care [2, 6]. In the Korean outbreak, the hospital was closed and disinfected twice, and no additional cases occurred after the last patient was discharged [2]. The psychological toll on veterinary staff, who may be faced with euthanizing their own patients or witnessing the rapid deterioration of animals under their care, is also significant. From a public health perspective, while FCV is not zoonotic, the outbreak dynamics serve as a valuable model for understanding the emergence and spread of highly virulent RNA viruses in healthcare settings, with parallels to norovirus outbreaks in human hospitals and the emergence of pandemic influenza strains.

The epidemiological data from these outbreaks have informed the development of evidence-based infection control protocols. The World Organisation for Animal Health (WOAH) and national veterinary authorities recommend that any cat presenting with pyrexia of unknown origin, limb edema, or cutaneous ulceration, particularly if it has a history of recent hospitalization or exposure to a high-density cat population, should be immediately isolated and tested for FCV-VSD [5, 17]. During an outbreak, all cats in the affected ward should be considered potentially infected, and strict barrier nursing protocols, including the use of dedicated footwear, gowns, and gloves, should be implemented. Environmental decontamination requires the use of disinfectants with proven efficacy against FCV, such as sodium hypochlorite (1:32 dilution of household bleach), accelerated hydrogen peroxide, or peracetic acid-based products, with a minimum contact time of 10 minutes [17]. Alcohol-based hand rubs are insufficient, and hand washing with soap and water is preferred. The cessation of all elective surgeries and non-essential admissions is often necessary to break the chain of transmission.

Diagnostic Approaches: Clinical, Hematological, and Molecular Detection

The diagnosis of feline calicivirus virulent systemic disease (FCV-VSD) represents one of the most formidable challenges in contemporary feline medicine, precisely because the condition defies easy categorization through any single diagnostic modality. Unlike many infectious diseases where a solitary laboratory test can provide definitive confirmation, FCV-VSD requires a sophisticated, multi-layered diagnostic framework that integrates clinical acumen, hematological profiling, serum biochemistry, advanced molecular detection, and, crucially, an understanding of the profound limitations inherent to each approach. The recognition that FCV-VSD can emerge sporadically within populations, affect adequately vaccinated individuals, and mimic other severe systemic illnesses mandates that the clinician maintain a high index of suspicion and deploy diagnostic resources strategically [2, 5, 6]. This section provides an exhaustive examination of the diagnostic armamentarium available for FCV-VSD, with particular emphasis on the pathophysiological basis of clinical and laboratory findings, the technical nuances of molecular detection platforms, and the interpretive challenges that arise from the extraordinary genetic plasticity of the virus.

Clinical Presentation: The Syndromic Foundation of Diagnosis

The clinical diagnosis of FCV-VSD begins with recognition of a constellation of clinical signs that, while not pathognomonic, collectively distinguish this condition from classic FCV-associated upper respiratory tract disease (FCV-URTD) and from other systemic febrile illnesses of cats. The hallmark clinical features consistently reported across outbreaks globally include profound pyrexia (frequently exceeding 40°C), severe lethargy progressing to prostration, and complete anorexia [2, 5, 16]. However, it is the cutaneous and subcutaneous manifestations that provide the most compelling visual evidence for FCV-VSD. Pitting edema of the limbs, particularly affecting the distal extremities and footpads, has been documented with remarkable consistency across outbreaks in North America, Europe, Asia, and Australia [1, 2, 4, 5]. Magliocca and colleagues described a case in a kitten where footpad edema was accompanied by severe pneumonia, highlighting that even very young animals can develop the full spectrum of VSD pathology [4]. The edema reflects a pathophysiological process of vascular compromise and increased capillary permeability, a feature that distinguishes VSD from classical FCV infection where such findings are conspicuously absent.

Cutaneous ulceration represents another critical clinical marker, with lesions frequently localizing to sites of minor trauma, venipuncture, surgical incision sites, or areas of friction [6]. Deschamps et al. documented an extreme flare-up of lesions at sites of skin breach in an outbreak within an intensive care unit in France, reporting that such localization precluded any further puncture or incision, a finding that underscores the profound vasculotropic nature of VS-FCV strains [6]. Ulcerative lesions on the pinnae, nasal planum, and periocular skin are common, while lingual and palatal ulcers, although also seen in classic FCV, tend to be more extensive and coalescing in VSD [5, 9]. Importantly, the oral ulcerations in FCV-VSD may extend beyond the typical dorsal tongue and hard palate distribution seen in URTD, involving the buccal mucosa, pharynx, and sometimes the esophagus [2, 16].

Respiratory signs in FCV-VSD can range from mild sneezing and serous nasal discharge to severe interstitial pneumonia, the latter being a frequent finding in fatal cases [4, 16]. Pedersen and colleagues, in their seminal description of the first recognized FCV-VSD outbreak, noted that some affected cats presented with a hemorrhagic-like fever syndrome, with petechiation, ecchymoses, and bloody nasal discharge, features that closely resembled rabbit hemorrhagic disease [16]. Ocular manifestations, while less prominent than in feline herpesvirus-1 infection, can include conjunctivitis, chemosis, and in severe cases, anterior uveitis [36]. The incubation period in naturally occurring outbreaks has been estimated at a median of 4.5 days, with clinical progression to severe disease occurring rapidly over 24–48 hours in many cases [6].

A critical clinical distinction must be made between FCV-VSD and other conditions that present with similar features. Feline panleukopenia virus (FPV) infection can cause severe systemic illness with fever and lethargy but is typically characterized by profound leukopenia and gastrointestinal signs rather than cutaneous edema and ulceration [3, 34]. Feline infectious peritonitis (FIP), particularly the non-effusive form, can present with pyrexia, vasculitis, and multi-organ involvement, but the characteristic granulomatous lesions, uveitis, and neurologic signs of FIP differ from the acute, rapidly progressive cutaneous and respiratory syndrome of FCV-VSD [26, 35, 37]. Co-infections are common and can complicate diagnosis; Caringella et al. documented concurrent FPV infection in cats with FCV-VSD in Italy, emphasizing the importance of comprehensive pathogen screening [3]. Systemic bacterial infections, severe sepsis, and immune-mediated diseases must also be considered in the differential diagnosis [34].

Hematological and Serum Biochemical Profiling

Hematological abnormalities in FCV-VSD are neither uniform nor pathognomonic, but certain patterns have emerged with sufficient consistency across outbreaks to warrant their inclusion in the diagnostic algorithm. The most consistently reported hematological finding is lymphopenia, which has been documented in the majority of FCV-VSD cases where complete blood counts were performed [2, 39]. Park and colleagues, in their analysis of a nosocomial outbreak in Korea involving 18 cats, reported that lymphopenia and macrothrombocytopenia were the most common hematological abnormalities [2]. Thrombocytopenia in FCV-VSD is particularly noteworthy because it is not a feature of classic FCV-URTD and may reflect the systemic vascular compromise and endothelial damage that characterize the disease [2, 16]. The presence of macrothrombocytes suggests accelerated platelet turnover and bone marrow response, consistent with a consumptive process. Leukopenia, while more characteristic of FPV infection, has been reported in some FCV-VSD cases, particularly in the early febrile phase [39]. Neutrophilia with a left shift may develop as the disease progresses, reflecting the systemic inflammatory response. Anemia, when present, is typically mild and may be multifactorial in origin, resulting from anorexia, inflammatory suppression of erythropoiesis, or blood loss from ulcerative lesions.

The serum biochemical profile in FCV-VSD frequently reveals evidence of multi-organ involvement, reflecting the systemic nature of the infection. Hyperbilirubinemia, often striking in its severity, has been documented in multiple outbreaks and likely reflects a combination of hepatic injury, hemolysis, and cholestasis [2, 39]. Elevated activities of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) indicate hepatocellular damage, while increased creatine kinase (CK) activity suggests muscle injury, which may be secondary to myositis, pressure necrosis from recumbency, or direct viral cytopathology [2]. Serum amyloid A (SAA), an acute phase protein, is markedly elevated in FCV-VSD, reflecting the intense systemic inflammatory response [2, 13]. Importantly, the magnitude of SAA elevation appears to correlate with disease severity, and serial monitoring may provide prognostic information. Azotemia, when present, may indicate prerenal dehydration or, in advanced cases, acute kidney injury secondary to hypoperfusion or direct viral injury [39]. Hypoalbuminemia is a common finding, likely resulting from a combination of decreased hepatic synthesis, protein-losing enteropathy, and vascular leakage into tissues [37].

The acute phase protein response in FCV-VSD deserves particular attention. Spiri and colleagues demonstrated that in experimentally infected cats, SAA concentrations were significantly higher in unvaccinated control animals compared to vaccinated cats, suggesting that the magnitude of the acute phase response correlates with viral replication and disease severity [13]. While SAA is not specific for FCV-VSD, its elevation in the appropriate clinical context, particularly when coupled with characteristic cutaneous findings, provides supportive evidence for a severe systemic inflammatory process. In contrast, cats with classic FCV-URTD typically show only mild, if any, acute phase protein alterations, making this a potentially useful differentiator in equivocal cases [13].

It is crucial to recognize that the absence of hematological or biochemical abnormalities does not exclude FCV-VSD, particularly in peracute cases where death may occur before significant laboratory alterations develop. Furthermore, the hematological profile of FCV-VSD can evolve rapidly, and serial monitoring is often more informative than a single time point. The lymphopenia and thrombocytopenia that characterize early disease may give way to a reactive leukocytosis as the inflammatory response progresses, and the timing of sample collection relative to disease onset must be considered when interpreting results [39].

Molecular Detection: Platforms, Targets, and Interpretive Pitfalls

Molecular detection of FCV RNA has become the cornerstone of laboratory diagnosis for FCV-VSD, offering sensitivity and speed that surpass traditional virus isolation [29, 32]. A variety of reverse transcription polymerase chain reaction (RT-PCR) platforms have been developed and validated, ranging from conventional gel-based assays to real-time quantitative PCR (RT-qPCR) and, most recently, isothermal amplification and CRISPR-based detection systems [14, 27, 29, 32]. The choice of platform, primer set, and target region significantly influences diagnostic performance, and an understanding of these technical variables is essential for accurate result interpretation.

Real-time RT-qPCR assays targeting conserved regions of the FCV genome offer the highest sensitivity and specificity for routine diagnosis. Abd-Eldaim and colleagues designed a TaqMan probe-based assay targeting the first 120 nucleotides of the 5′ region of the genome, which they demonstrated to be highly conserved among genetically diverse FCV isolates [32]. This assay showed sensitivity and specificity equivalent to virus isolation when tested against 122 clinical samples, with the advantage of providing results within hours rather than days [32]. Zhao and colleagues developed a similar TaqMan RT-qPCR assay with a reported limit of detection of 9.6 × 10⁰ copies/μL, demonstrating linear detection across a nine-log dynamic range [29]. Importantly, they showed that RT-qPCR had significantly higher detection rates than conventional RT-PCR in samples with low viral loads, a critical advantage when testing samples from cats with early or mild disease [29]. In their analysis of 100 clinical samples from cats across China, the RT-qPCR assay detected FCV in a higher proportion of cases than conventional PCR, particularly in samples collected from the anal region during later stages of infection [29].

The selection of clinical sample type is a critical determinant of diagnostic sensitivity. Oropharyngeal swabs have consistently yielded the highest detection rates, followed by nasal and conjunctival swabs [14, 15, 29]. Acar and colleagues, comparing PCR and virus isolation across 331 diagnostic samples from 107 cats, found that oropharyngeal swabs provided the highest positivity rate (23.08%), compared to nasal (15.24%) and conjunctival (14.02%) swabs [14]. Importantly, testing multiple sample types from the same animal increases overall detection sensitivity, as viral shedding may be intermittent or localized [14, 15]. In cases of suspected FCV-VSD, whole blood or serum should also be submitted for molecular testing, as RNAemia is a common feature of systemic infection and its detection provides strong evidence for disseminated disease rather than localized respiratory infection [2, 5, 13, 29]. Duclos and colleagues reported that detection of FCV RNA in blood by RT-PCR, followed by a negative result after clinical resolution, provided definitive confirmation of systemic infection in the first reported case of FCV-VSD in Ireland [5].

Virus isolation remains a valuable adjunct to molecular detection, particularly for characterizing novel strains and for cases where PCR results are equivocal or negative despite strong clinical suspicion [14, 16, 38]. FCV can be isolated on Crandell-Rees feline kidney (CRFK) cells or other permissive cell lines, with cytopathic effect (CPE) typically appearing within 24–72 hours [16, 19, 38]. However, virus isolation is more time-consuming and technically demanding than PCR, and its sensitivity is lower, particularly for samples with low viral loads or those that have been improperly stored [14]. Acar and colleagues found that virus isolation detected FCV in only 19.63% of samples compared to higher detection rates by nested RT-PCR [14]. Nevertheless, virus isolation provides the advantage of yielding live virus for subsequent characterization, including determination of antigenic phenotype, growth kinetics, and sensitivity to antiviral compounds [1, 19, 33]. For epidemiological surveillance and outbreak investigations, virus isolation coupled with whole genome sequencing remains the gold standard for understanding viral evolution and transmission dynamics [1, 19, 21, 22].

Novel molecular platforms are expanding the diagnostic toolkit for FCV detection. Zhang and colleagues developed a CRISPR/Cas13a-based lateral flow dipstick (LFD) assay that couples the specificity of CRISPR-mediated RNA recognition with the convenience of a point-of-care format [27]. This assay, which targets the conserved ORF1 region, demonstrated high specificity against a panel of feline pathogens and a sensitivity comparable to RT-qPCR, with the advantage of providing visual results within 30–40 minutes without the need for specialized thermocycling equipment [27]. While still in the validation phase for clinical use, such platforms hold promise for rapid, on-site diagnosis in outbreak settings, particularly in resource-limited environments. High-resolution melting (HRM) analysis represents another emerging approach that can simultaneously detect FCV and differentiate between vaccine and field strains based on melting curve profiles [25]. Phongroop and colleagues demonstrated that HRM could distinguish between two commercial vaccine strains and five wild-type Thai FCV strains in a single PCR reaction, offering a potential tool for investigating vaccine-breakthrough cases [25].

The Interpretive Challenge: Molecular Detection Cannot Distinguish Pathotypes

Perhaps the most critical concept in the molecular diagnosis of FCV-VSD is that detection of FCV RNA, by any platform, does not differentiate between virulent systemic and classic respiratory strains. This limitation has been repeatedly demonstrated across diverse geographic settings and experimental systems [1, 3, 4, 7, 24]. Bordicchia and colleagues, in their comprehensive analysis of three Australian outbreaks, performed metagenomic sequencing on multiple isolates and identified five genetically distinct FCV lineages, yet could not identify any mutation that clearly distinguished FCV-URTD from FCV-VSD phenotypes [1]. Similarly, Caringella and colleagues, reporting on Italian cases, confirmed that VS-FCV strains did not show consistent amino acid sequence changes relative to reference strains [3]. Magliocca and colleagues, in their detailed analysis of a kitten with fatal VSD, found that the ORF2 sequences amplified from multiple affected tissues were identical and phylogenetically indistinguishable from URTD strains [4].

The hypervariable E region of the capsid protein

Genetic Diversity and Evolutionary Lineages in FCV-VSD Outbreaks

The emergence of virulent systemic disease (VSD) associated with feline calicivirus (FCV) represents one of the most perplexing and clinically challenging phenomena in contemporary feline medicine. Unlike the relatively stable genomic architecture observed in many DNA viruses, FCV exists in a state of perpetual genetic flux, driven by the error-prone nature of its RNA-dependent RNA polymerase (RdRp), which lacks proofreading capacity. This intrinsic mutability, combined with homologous recombination and sustained selective pressures from host immunity and vaccination, generates a dynamic population structure wherein VSD-associated lineages can arise sporadically and seemingly de novo from circulating upper respiratory tract disease (URTD) strains [1, 10, 17]. The central enigma, why certain FCV strains acquire the capacity to cause systemic vascular compromise and multi-organ failure while the vast majority remain confined to the oronasal mucosa, has driven intensive molecular epidemiological investigation across multiple continents.

The Quasispecies Paradigm and Genetic Plasticity

FCV, like other caliciviruses, circulates as a complex and highly heterogeneous quasispecies. The viral genome, approximately 7.7 kb in length, comprises three open reading frames (ORFs): ORF1 encodes the nonstructural proteins (including the protease-polymerase), ORF2 encodes the major capsid protein VP1, and ORF3 encodes the minor structural protein VP2 [19, 20]. The VP1 capsid protein, particularly its hypervariable E region, is the primary target of neutralizing antibodies and, consequently, the most genetically plastic domain of the genome. This region, which interacts with the cellular receptor junctional adhesion molecule A (FeJAM-1) and the VP2 protein during viral entry, undergoes continuous amino acid substitution under immune pressure [7, 20]. The rate of nucleotide substitution in FCV is estimated to be on the order of (10^{-3}) to (10^{-4}) substitutions per site per year, comparable to other rapidly evolving RNA viruses such as human norovirus and influenza A virus.

This high mutation rate underpins the repeated, independent emergence of VSD-associated lineages across geographically disparate regions. Critically, comparative genomic analyses of VSD and URTD isolates have repeatedly failed to identify a single, conserved set of virulence determinants that consistently distinguishes the two pathotypes [1, 3, 4]. For instance, Bordicchia et al. (2021) performed metagenomic sequencing on five genetically distinct FCV lineages recovered from three Australian VSD outbreaks. Despite clear phenotypic differences in clinical presentation and mortality (39% overall mortality in that study), no specific nucleotide or amino acid signature could universally differentiate the VSD isolates from contemporaneous URTD strains [1]. Similarly, Italian VSD isolates characterized by Caringella et al. (2019) formed a unique phylogenetic cluster but did not exhibit consistent amino acid changes relative to reference VSD strains, further complicating the search for molecular markers [3]. These findings strongly suggest that VSD pathogenicity is not conferred by a single "virulence gene" but rather emerges from complex, context-dependent interactions between specific combinations of mutations, host immune status, and environmental factors.

Global Phylogenetic Lineages and Recombination Events

Phylogenetic analyses of FCV strains globally have consistently resolved two major genogroups, GI and GII, with a predominance of GII strains in Asia [18, 21, 23]. However, VSD outbreaks do not segregate neatly within a single genogroup or clade. Instead, VSD-associated isolates are interspersed among classical URTD strains across the phylogenetic tree, indicating that the virulent phenotype has arisen multiple times independently from diverse ancestral backgrounds. In China, the SH/2014 strain, a prototypical VSD isolate, clustered with the US-origin George strain and other reported VSD strains within a single clade, yet other Chinese VSD isolates grouped separately, suggesting multiple independent emergence events within a large geographical entity [19]. In Thailand, Phongroop et al. (2024) demonstrated that all 14 characterized FCV-Thai strains clustered within genogroup I, with no evidence of inter-genogroup recombination, but one strain exhibited a vaccine-like VP1 sequence, highlighting the capacity for vaccine strain reversion or recombination with field strains [25, 31].

Recombination is a major driver of FCV genetic diversity and is particularly implicated in the genesis of VSD lineages. Lee et al. (2021) provided compelling evidence of intergenic recombination in a Korean VSD-associated strain, FCV 14Q315, which was recovered from a cat with hemorrhagic-like disease. Their recombination analysis revealed a clear crossover event within ORF1, between the p30 coding region and the ORF1/ORF2 junction. The non-recombinant portion of ORF1 showed high similarity to Korean and Chinese field strains (GX2019, CH-JL2), while the recombinant region was derived from the US-origin UTCVM-H1 strain, which is itself associated with hemorrhagic disease [22]. This finding demonstrates that VSD-associated genetic elements can be introduced into circulating strains via recombination, potentially accelerating the emergence of novel virulent variants. Similarly, Bordicchia et al. (2021) identified one URTD strain that likely originated from a recombination event, underscoring the role of genetic exchange in generating the diversity from which VSD strains can arise [1].

The Enigmatic E Region: Structural Determinants of Pathogenicity?

Despite the absence of universal virulence markers, a growing body of evidence implicates specific amino acid residues within the hypervariable E region of VP1 in modulating pathogenicity. The E region is a structurally flexible loop that mediates receptor binding and is exposed on the virion surface. Brunet et al. (2019) employed an innovative multiple correspondence analysis (MCA) of amino acid physicochemical properties within this region. This approach successfully differentiated VSD from classical URTD strains for the first time, identifying seven statistically significant residue positions, primarily located in the N-terminal hypervariable portion of region E, that correlated with pathotype [7]. Structural modeling suggested that these residues interact either with FeJAM-1 or with the minor capsid protein VP2, raising the hypothesis that post-binding conformational changes differ between pathotypes, potentially altering tropism and facilitating systemic spread.

Subsequent work by Liu et al. (2021) on two Chinese isolates, QD-7 (asymptomatic) and QD-164 (causing typical URTD), focused on a specific NNS motif at amino acid positions 441–443 within the E region. This motif, previously associated with highly virulent strains, was absent in the attenuated QD-7 strain but present in QD-164, which caused more severe clinical signs [24]. The presence of an asparagine (N) residue at position 442 appeared to correlate with increased disease severity, although the study acknowledged that this single motif was insufficient to explain the full spectrum of virulence. Intriguingly, Luo et al. (2025) identified amino acid variation in the VP1 E region between two GII genotype strains from China, SH23-13 (VSD phenotype) and GD23-02 (URTD phenotype), yet both strains caused oral ulcers and diarrhea, demonstrating that seemingly subtle sequence differences can result in distinct disease progression patterns [21]. These observations collectively indicate that the E region harbors critical determinants of tropism and pathogenicity, but that virulence is likely polygenic and epistatic, requiring specific combinations of residues across multiple regions of the genome.

Lineage Diversification and Adaptive Radiation

The evolutionary history of FCV is characterized by periodic lineage extinction and replacement, driven by immune selection and vaccine pressure. In Korea, Park et al. (2024) documented two nosocomial VSD outbreaks over a six-month period in a referral hospital, with an overall mortality rate of 72.2% [2]. Notably, the outbreaks were controlled only after complete hospital closure and disinfection, and no further cases occurred. This pattern of rapid, focal emergence and subsequent extinction is typical of VSD outbreaks, suggesting that highly virulent lineages often fail to establish long-term circulation, possibly due to their high case-fatality rates limiting transmission opportunities.

In contrast, in Australia, Bordicchia et al. (2021) identified five genetically distinct lineages across three outbreaks, all of which appeared to have evolved in situ rather than being the result of a single imported strain [1]. This finding implies that VSD lineages can arise independently from local, low-virulence precursors, and that the conditions for such emergence, high density, immune naivety, and co-circulation of multiple strains, are met repeatedly in different geographic contexts. Similarly, in Europe, VSD outbreaks have been reported in the United Kingdom, France, Italy, Switzerland, and Ireland, with each outbreak strain generally forming a unique phylogenetic cluster [3, 5, 6, 11]. The Irish case, first reported by Duclos et al. (2024), involved an 11-month-old vaccinated cat with pitting edema and lingual ulcers; the source was traced to a recently introduced shelter kitten, illustrating the role of high-density shelter environments as crucibles for VSD emergence [5].

Vaccination exerts a powerful selective force on FCV evolution. The widespread use of modified-live vaccines (e.g., F9 strain) over several decades has driven antigenic diversification, with field strains progressively diverging from vaccine strains. This is evidenced by the low neutralization titers observed against VSD isolates in vaccinated cats [16, 17]. Although vaccination reduces disease severity and viral shedding, it does not prevent infection, allowing vaccine-escape mutants to circulate and potentially accumulate virulence-associated mutations [12, 13]. The emergence of vaccine-like variants in field settings, as reported in Thailand [31], further underscores the complex interplay between vaccination and viral evolution.

Implications for Surveillance and Control

The genetic diversity and evolutionary dynamics of FCV demand a fundamentally different approach to disease surveillance compared with more antigenically stable pathogens. The World Organisation for Animal Health (WOAH) recognizes the global significance of emerging calicivirus diseases, and the sporadic, unpredictable nature of VSD outbreaks aligns with the criteria for emerging infectious diseases requiring active monitoring. The absence of a stable phylogenetic marker for VSD means that molecular surveillance cannot rely on PCR-based pathotyping alone; instead, comprehensive genomic epidemiology, integrating full-genome sequencing, phylogenetic analysis, and in vivo or in vitro virulence assessment, is essential.

Furthermore, the role of recombination in generating VSD lineages underscores the need for surveillance systems capable of detecting mixed infections. As demonstrated in Korea [22] and Australia [1], recombination between low-virulence strains can generate novel virulent recombinants. Therefore, diagnostic protocols should prioritize sequencing of the complete ORF1-ORF2 junction region, where recombination breakpoints frequently occur. The development of robust reverse genetics systems for VSD strains, such as those established for the Chinese SH/2014 strain [41] and the replication-deficient vaccine platform recently described [18, 40], provide powerful tools for dissecting the molecular determinants of virulence and for testing the protective breadth of next-generation vaccines.

In summary, the genetic diversity and evolutionary lineages underpinning FCV-VSD outbreaks are characterized by extreme plasticity, recurrent independent emergence, and a polygenic basis for virulence. The lack of a single, conserved molecular marker for the VSD phenotype is itself a defining feature of the pathotype, reflecting the capacity of a highly mutable RNA virus to explore diverse sequence space and arrive at a virulent state through multiple evolutionary trajectories. Only through sustained, globally coordinated genomic surveillance and functional characterization of emerging variants can the veterinary community hope to anticipate, contain, and ultimately prevent future VSD epizootics.

Antiviral Therapeutics: In Vitro Efficacy and Translational Potential

The management of feline calicivirus virulent systemic disease (FCV-VSD) remains profoundly hampered by the conspicuous absence of any licensed, specific antiviral therapy. The clinical reality, underscored by mortality rates ranging from 39% to a staggering 79% in documented outbreaks [1, 2, 6], demands an urgent and rigorous exploration of pharmacological interventions. While vaccination against FCV is a core preventive measure, its limitations, specifically, the failure to prevent infection or shedding, and the documented vaccine breakthrough events by emergent VS-FCV strains [13, 16, 17], render it insufficient for outbreak control or the treatment of active, fulminant disease. This critical therapeutic void has catalyzed a surge in research identifying and characterizing a diverse array of antiviral candidates. The translational pipeline from in vitro discovery to in vivo validation, however, is fraught with challenges, including the high genetic plasticity of the virus, the need for potent activity against diverse field strains, and the establishment of optimal dosing and safety profiles in the feline patient.

Direct-Acting Antivirals: Targeting the Viral Machinery

The most straightforward approach to antiviral therapy involves directly inhibiting essential viral enzymes. The FCV genome encodes a nonstructural polyprotein that is cleaved by a viral protease to yield functional proteins, including an RNA-dependent RNA polymerase (RdRp). These represent high-value drug targets. Seminal work by Fumian et al. established robust, recombinant enzyme-based in vitro assays to specifically screen for inhibitors of the FCV protease and polymerase [33]. This study identified quercetagetin and PPNDS as inhibitors of the FCV polymerase, with IC₅₀ values of 2.8 μM and 2.7 μM, respectively [33]. However, a critical disconnect emerged: neither compound demonstrated antiviral activity in cell culture-based assays, likely due to poor cell permeability or intracellular instability, highlighting the essential step of whole-cell validation for any promising hit [33].

Conversely, nucleoside analogues, which are prodrugs that are phosphorylated intracellularly to their active triphosphate form to inhibit the RdRp, have shown considerable promise. 2′-C-methylcytidine (2CMC) and NITD-008 are two such compounds that have been rigorously tested against FCV-VSD isolates. Bordicchia et al. demonstrated that 2CMC possesses potent in vitro activity against multiple Australian FCV-VSD strains, with a half-maximal effective concentration (EC₅₀) ranging from 2.7 to 5.3 µM [1]. The selectivity index (TI > 18) is moderate, suggesting a reasonable window between efficacy and cytotoxicity. More impressively, NITD-008, another nucleoside analogue, exhibited even greater potency (EC₅₀ of 0.5 to 0.9 µM) and an exceptionally high selectivity index (TI > 111) [1]. This robust profile positions NITD-008 as a highly attractive candidate for further development, although its pharmacokinetic and safety profile in cats remains to be fully elucidated. Another study reinforced the efficacy of 2CMC, reporting an EC₅₀ of 2.5 µM against a laboratory FCV strain, further corroborating its potential as a broad-spectrum anti-FCV agent [33]. The efficacy of these compounds against a panel of genetically distinct FCV-VSD field strains [1] is particularly encouraging, suggesting that the RdRp active site is sufficiently conserved to overcome some of the viral genetic diversity that plagues vaccine efficacy.

Host-Targeting Agents: Exploiting Cellular Vulnerabilities

An alternative, and increasingly popular, antiviral strategy is to target host cellular factors that are essential for viral replication but non-essential for cell survival. This approach theoretically presents a higher barrier to the development of viral resistance, as the virus cannot easily bypass a requirement for a host protein by simply mutating its own genome.

Nitazoxanide (NTZ), a thiazolide compound originally developed as an antiprotozoal agent, has emerged as a leading candidate for FCV therapy. Its mechanism of action is pleiotropic, involving the modulation of host innate immune responses and interference with viral replication at multiple stages. Against Australian FCV-VSD isolates, NTZ displayed potent in vitro activity with an EC₅₀ of 0.4–0.6 µM and a TI of 21 [1]. These findings were replicated and extended in a separate study, which demonstrated that NTZ inhibited a panel of different FCV strains in F81 cells [43]. Critically, this work also revealed a synergistic antiviral effect between NTZ and mizoribine, an immunosuppressant with antiviral properties, in the same in vitro system [43]. This combination strategy could potentially allow for lower doses of each drug, minimizing toxicity while maintaining or enhancing antiviral efficacy.

The translational potential of NTZ is further substantiated by successful in vivo challenge studies. Cats experimentally infected with FCV and treated with NTZ exhibited significantly reduced clinical scores, lower viral loads in the trachea and lungs, and decreased viral shedding compared to untreated controls [43]. This proof-of-concept in vivo data is a critical step towards clinical deployment, as NTZ is already an approved drug in human medicine with a well-characterized safety profile, potentially facilitating its repurposing for veterinary use.

Another innovative host-targeted approach involves the inhibition of heat shock protein 70 (HSP70). Through a high-throughput screen of 1746 traditional Chinese medicine monomer compounds, Yan et al. identified handelin as a potent inhibitor of FCV replication, with an EC₅₀ of approximately 2.5 µM [42]. Their mechanistic studies demonstrated that handelin exerts its antiviral effect by interfering with HSP70 expression. HSP70 is a molecular chaperone that plays a crucial, positive role in the FCV life cycle, likely by aiding in viral protein folding or assembly [42]. By targeting this host dependency factor, handelin and other HSP70 inhibitors (like VER-155008, also shown to be active) offer a novel and promising avenue for broad-spectrum antiviral activity, as HSP70 is a common target for many viruses [42].

Lapachol, a naphthoquinone compound, represents yet another distinct host-targeting strategy. A recent drug screen identified it as a potent anti-FCV agent with an EC₅₀ of 1.87 µM and an extraordinarily high SI of 677 [45]. Mechanistic studies revealed that lapachol acts by inhibiting feline dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine biosynthesis pathway [45]. By depriving the rapidly replicating virus of a sufficient nucleotide pool, lapachol effectively halts viral genome replication. The high selectivity index suggests that host cells may be able to utilize salvage pathways for pyrimidine acquisition, providing a therapeutic window. The in vivo potential of lapachol is exceptionally promising; oral administration at 5 mg/kg to FCV-infected cats significantly reduced oral and nasal viral shedding, promoted recovery from weight loss, and alleviated oral ulcerations and pulmonary lesions without observable hepatotoxicity or nephrotoxicity [45]. The identification of DHODH as a viable target for FCV opens a new class of drugs for veterinary use.

Broad-Spectrum and Combination Approaches

The antiviral activity of poly(sodium 4-styrene sulfonate) (PSSNa) is of particular interest due to its unique mechanism of action as a polyanionic compound. PSSNa is believed to act as a viral entry inhibitor, disrupting the initial electrostatic interaction between the positively charged virus capsid and the negatively charged host cell surface. A preliminary, double-blind, placebo-controlled field study by Synowiec et al. tested the topical oral application of PSSNa as an adjunct therapy in cats with FCV-associated oral disease. The results showed a statistically significant decrease in viral load in the treatment group compared to placebo, alongside improvement in disease symptoms [44]. While the study had notable limitations, including inconsistent owner administration and small sample size, it provides initial evidence that PSSNa, applied topically, can have a measurable in vivo effect [44]. This approach may be particularly valuable for managing the oral component of FCV infection and reducing environmental shedding.

The synergistic effect observed between nitazoxanide and mizoribine [43] underscores the immense potential of combination therapy to combat FCV. The high mutation rate of this RNA virus means that monotherapy, particularly with a direct-acting antiviral, carries a significant risk of selecting for resistant mutants. Combining drugs with different mechanisms of action, for example, a host-targeting agent like NTZ with a direct-acting RdRp inhibitor like 2CMC, could dramatically increase the genetic barrier to resistance, provide additive or synergistic antiviral effects, and potentially allow for lower, less toxic doses of each individual drug. This paradigm, well-established in the management of human viral infections such as HIV and Hepatitis C, should be a central pillar of future FCV-VSD therapeutic development.

Bridging the Translational Gap

Despite the impressive in vitro potency and promising early in vivo data for several compounds, a substantial translational gap remains before any of these agents can become routine clinical tools for FCV-VSD. The field data for PSSNa [44] and the in vivo success with NTZ [43] and lapachol [45] are encouraging, but these studies are limited in scale and often lack blinding or robust controls needed for regulatory approval. The challenge is amplified by the very nature of FCV-VSD: it is a rapidly progressive, often sporadic disease with high mortality, making the design of large-scale, prospective, randomized controlled clinical trials exceptionally difficult. Furthermore, the genetic heterogeneity of the FCV-VSD pathotype itself [1, 3] means that an antiviral must demonstrate efficacy against a broad panel of diverse isolates, not just a single laboratory strain. The work of Bordicchia et al., which tested compounds against multiple outbreak strains, sets a critical standard for future antiviral research [1].

In conclusion, the landscape of antiviral therapeutics for FCV-VSD is rich with potential. From direct-acting nucleoside analogues like NITD-008 and 2CMC to host-targeting agents like nitazoxanide, lapachol, and handelin, a diverse arsenal of molecules with distinct mechanisms is being assembled. The future of FCV-VSD pharmacotherapy almost certainly lies in the strategic deployment of combination regimens, leveraging synergies between host-targeted and virus-targeted drugs to maximize efficacy, minimize toxicity, and prevent the emergence of resistance. The urgent next steps must involve rigorous pharmacokinetic and toxicological studies in cats, followed by controlled, multi-center field trials designed to evaluate these promising candidates in the clinical settings where they are so desperately needed.

Prevention, Biosecurity, and Infection Control Strategies

The prevention and control of Feline Calicivirus Virulent Systemic Disease (FCV-VSD) demands a multi-layered, rigorously enforced strategy that transcends the protocols applied to classical FCV upper respiratory tract disease (URTD). The unique epidemiological characteristics of VS-FCV, its extreme contagiousness, environmental persistence, high mortality (ranging from 39% to 86% in reported outbreaks [1, 2, 6]), and ability to cause disease in adequately vaccinated cats [5, 16], necessitate a paradigm shift in how veterinary facilities, shelters, and multi-cat households approach infection control. The cornerstone of this strategy rests upon three interdependent pillars: (1) comprehensive vaccination programs optimized for cross-protection, (2) stringent biosecurity protocols designed to interrupt nosocomial and environmental transmission, and (3) rapid, sensitive diagnostic surveillance to enable early detection and containment. Failure in any one of these domains can precipitate devastating epizootics, as evidenced by multiple hospital-acquired outbreaks documented globally [2, 6, 9].

Vaccination: Limitations, Optimization, and Emerging Strategies

Vaccination remains the most critical prophylactic measure against FCV, yet its role in preventing VS-FCV is nuanced and often misunderstood. All currently available commercial vaccines are classified as core by the European Advisory Board on Cat Diseases (ABCD) and major veterinary organizations [17]. However, these vaccines, predominantly based on the F9 strain or related FCV strains, are designed to protect against severe disease, not to prevent infection or viral shedding [12, 13, 17]. This distinction is paramount: vaccinated cats can still become infected with heterologous VS-FCV strains, develop clinical signs, and serve as sources of contagion [5, 16]. The high genetic plasticity of FCV, driven by its RNA-dependent RNA polymerase with an estimated mutation rate of approximately 10⁻³ to 10⁻⁴ substitutions per nucleotide per year, results in continuous antigenic drift that can render vaccine-induced neutralizing antibodies less effective against emerging field strains [8, 10, 23].

Mechanisms of Vaccine-Induced Protection: Despite these limitations, vaccination confers significant benefits. Modified-live virus (MLV) vaccines, such as those containing the F9 strain, have been demonstrated to induce a robust Th1-polarized cellular immune response, characterized by the activation of interferon (IFN)-γ-releasing peripheral blood mononuclear cells (PBMCs) and upregulation of cytotoxic mediators including perforin and granzyme B [12]. This cellular immunity appears to be more cross-reactive than the humoral response, providing a critical second line of defense against heterologous challenge. In experimental challenge studies, vaccinated cats exhibited significantly lower clinical scores, reduced pyrexia, diminished acute-phase protein responses, and, notably, a marked reduction in both the duration and magnitude of viral RNAemia and oropharyngeal shedding compared to unvaccinated controls [13]. This reduction in shedding is epidemiologically crucial, as it directly decreases the environmental viral load and the probability of transmission to susceptible cohorts.

Optimizing Vaccine Protocols: Given the antigenic diversity of circulating FCV strains, including VS-FCV variants, several strategies have been proposed to enhance vaccine efficacy. The ABCD has suggested that in facilities experiencing breakthrough infections in fully vaccinated cats, switching to a vaccine containing a different FCV strain (e.g., from F9 to a strain such as 255 or G1) may broaden the spectrum of cross-neutralizing antibodies within the population [17]. More compellingly, a landmark study demonstrated that the route of administration profoundly impacts protective efficacy. Subcutaneous (SC) administration of a 4-way vaccine followed by a booster dose administered orally (SC/Oral) reduced mortality against a highly virulent VS-FCV challenge (strain 33585) to just 10%, compared to 44% mortality in cats receiving two SC doses and 78% mortality in unvaccinated controls [30]. The proposed mechanism involves enhanced mucosal immunity, including the induction of secretory IgA at oropharyngeal and respiratory mucosal surfaces, which may provide superior neutralization at the primary portal of viral entry. This finding has profound implications for catteries and shelters, where oral vaccination as a booster could be a practical and life-saving intervention.

Emerging Vaccine Technologies: The limitations of traditional vaccines have spurred development of next-generation platforms. A replication-deficient FCV vaccine, generated by partial deletion of the VP2 gene (rHBDL2 FCV-ΔVP2), has shown exceptional promise. This platform cannot complete its replication cycle, eliminating the risk of reversion to virulence, a theoretical concern with MLV vaccines. Immunization with this construct induced high levels of neutralizing antibodies and significantly reduced clinical signs upon homologous VS-FCV challenge [40]. Critically, by combining two replication-deficient constructs expressing genetically distant VP1 genes, researchers achieved broad neutralization activity against diverse FCV strains, including heterologous GI and GII genotypes [18, 40]. This "cocktail" approach directly addresses the antigenic variability problem and represents a paradigm shift in FCV vaccinology. Furthermore, the identification of the Chinese isolate HBDL2, which elicits broadly neutralizing antibodies against multiple VS-FCV strains, suggests that careful strain selection for vaccine antigens can yield superior cross-protection [18].

Biosecurity in Veterinary Facilities: Interrupting Nosocomial Transmission

Nosocomial outbreaks of FCV-VSD represent the most feared manifestation of this pathogen, with mortality rates reaching 79% in some hospital settings [6]. The 2011 outbreak in a French veterinary ICU, where 14 cats were affected over a median incubation period of just 4.5 days, serves as a stark reminder of the speed with which VS-FCV can propagate within a clinical environment [6]. Similarly, a Korean referral hospital experienced two distinct outbreaks over six months, affecting 18 cats with a 72.2% mortality rate, necessitating complete hospital closure and double disinfection [2]. These events underscore that standard infection control protocols, adequate for classical FCV-URTD, are insufficient for VS-FCV.

Routes of Transmission and Environmental Persistence: VS-FCV is shed in extraordinarily high titers from oropharyngeal secretions, nasal discharge, conjunctival exudate, and, notably, blood and feces [4, 28, 29]. Transmission occurs primarily via direct contact, but fomites, including stethoscopes, thermometers, examination tables, food bowls, and, most critically, the hands and clothing of veterinary personnel, are potent vectors [6, 8]. The virus is non-enveloped and exhibits remarkable environmental stability; it can persist on dry surfaces at room temperature for weeks and is resistant to many common disinfectants, particularly quaternary ammonium compounds and alcohols [17]. This resistance mandates the use of specific, validated virucidal agents.

Core Biosecurity Protocols: The following measures are non-negotiable in any facility admitting cats, particularly during suspected or confirmed VS-FCV outbreaks:

1. Immediate Triage and Isolation: Any cat presenting with pyrexia of unknown origin, limb edema, cutaneous ulcerations (especially at venipuncture or surgical sites), or lingual ulcers should be immediately considered a VS-FCV suspect [5, 6]. Such patients must be housed in strict isolation, ideally in a separate air-handling zone with negative pressure ventilation. Dedicated equipment (stethoscopes, thermometers, bowls) must remain in the isolation ward and be disinfected with 0.5% sodium hypochlorite (1:10 dilution of household bleach) or 2% accelerated hydrogen peroxide, which have demonstrated efficacy against FCV [17].

2. Hand Hygiene and Personal Protective Equipment (PPE): The French outbreak investigation explicitly identified caregivers' hands as the primary vector of spread [6]. Strict hand hygiene with soap and water (alcohol-based sanitizers are insufficient against non-enveloped viruses) must be performed before and after every patient contact. For any suspect or confirmed case, full barrier PPE, including disposable gowns, gloves, and shoe covers, must be worn and discarded within the isolation area. Reusable items like stethoscopes must be dedicated to the isolation ward.

3. Cohorting and Traffic Flow: Suspect and confirmed cases should be cohorted separately. Uninfected, low-risk cats should be housed in a completely separate area, and staff should attend to these patients first before entering isolation zones. A "one-way" traffic flow from clean to contaminated areas should be enforced.

4. Environmental Decontamination: Following discharge or death of a VS-FCV patient, the entire enclosure must be terminally cleaned. All organic material must be removed with a detergent prior to application of a disinfectant with proven efficacy against FCV. Sodium hypochlorite (0.5%) remains the gold standard, though it is corrosive. Peroxygen compounds (e.g., 1-2% Virkon S) and chlorine dioxide are acceptable alternatives. Phenolic compounds are also effective but may be toxic to cats. Fumigation with formaldehyde or hydrogen peroxide vapor may be considered for large-scale decontamination of entire wards [2].

5. Cessation of Admissions and Elective Procedures: During an active outbreak, all non-emergency admissions, elective surgeries (including ovariohysterectomy, which has been associated with postoperative VS-FCV-like outbreaks [9]), and outpatient consultations should be suspended. The facility should remain closed to new feline admissions until a minimum of two weeks have passed since the last clinical case and terminal cleaning has been completed [2].

Surveillance, Early Detection, and Population-Level Control

The adage "you cannot control what you cannot measure" is profoundly applicable to FCV-VSD. Rapid, sensitive diagnostic capacity is the linchpin of effective outbreak management.

Diagnostic Tools for Surveillance: Reverse transcription quantitative PCR (RT-qPCR) targeting conserved regions of the FCV genome, such as the 5' untranslated region or the ORF1 polymerase gene, is the method of choice for rapid detection [29, 32]. These assays can detect as few as 10 copies of viral RNA and provide results within hours, enabling immediate implementation of control measures [29]. However, due to the high genetic diversity of FCV, reliance on a single primer set can yield false negatives; therefore, using multiple primer sets or including virus isolation in parallel is recommended for comprehensive surveillance [14]. Novel point-of-care technologies, such as CRISPR/Cas13a-based lateral flow dipsticks, are under development and promise to bring rapid, field-deployable detection to shelters and smaller clinics [27].

Monitoring Viral Shedding: Understanding the kinetics of viral shedding is critical for making evidence-based decisions regarding the release of cats from isolation. RT-qPCR data from experimental infections demonstrate that oropharyngeal and nasal swabs contain the highest viral loads during the first 9 days of infection, after which viral RNA shifts to fecal shedding, which can persist for up to 17 days or longer [29]. Therefore, a negative oropharyngeal swab alone is insufficient to declare a cat non-infectious; serial sampling of both oropharyngeal and rectal swabs, with negative results on at least two consecutive occasions 48-72 hours apart, should be required before a cat is removed from isolation.

Population-Level Strategies in Shelters and Catteries: In multi-cat environments, the prevalence of FCV carriage can exceed 40%, even among clinically healthy cats [14, 15]. Asymptomatic carriers are the primary reservoir for viral persistence and the source of new outbreaks [8, 15]. The following strategies are recommended:

• Reduction of Group Size: Epidemiological modeling and field data consistently identify group housing as a major risk factor for FCV infection [15]. Reducing the number of cats per enclosure, minimizing population density, and avoiding mixing of different social groups are highly effective non-specific interventions.
• Quarantine of New Arrivals: All new cats entering a shelter or cattery should be quarantined for a minimum of 14-21 days in a separate airspace. During this period, they should be monitored daily for clinical signs and, ideally, tested by RT-qPCR for FCV carriage before introduction to the general population.
• Vaccination of All Cats: Universal vaccination of all cats in a facility, including those with prior natural infection (as infection-induced immunity is not life-long [17]), is essential. The use of a booster oral vaccine, as described above, may offer additional mucosal protection [30].
• Culling as a Last Resort: In extreme, uncontrolled outbreaks with ongoing transmission despite maximal biosecurity, depopulation of affected rooms or entire facilities has been employed to eradicate the virus [2]. This is a measure of last resort, but it underscores the devastating potential of VS-FCV and the absolute necessity of proactive prevention.

In conclusion, the prevention of FCV-VSD requires a proactive, scientifically grounded, and rigorously enforced strategy. It demands a shift from reactive crisis management to a culture of continuous biosecurity, where vaccination is optimized, environmental decontamination is validated, and surveillance is relentless. Veterinary professionals must recognize that the emergence of VS-FCV has fundamentally altered the risk calculus for feline infectious disease management, and only through a comprehensive, multi-modal approach can the devastating impact of this pathogen be mitigated.

References

[1] Bordicchia M, Fumian T, Brussel KV, Russo AG, Carrai M, Le S, et al.. Feline Calicivirus Virulent Systemic Disease: Clinical Epidemiology, Analysis of Viral Isolates and In Vitro Efficacy of Novel Antivirals in Australian Outbreaks. Viruses. 2021. DOI: https://doi.org/10.3390/v13102040

[2] Park J, Lee D, Hong Y, Hwang C, Hyun J. Outbreaks of nosocomial feline calicivirus-associated virulent systemic disease in Korea. Journal of Veterinary Sciences. 2024. DOI: https://doi.org/10.4142/jvs.24030

[3] Caringella F, Elia G, Decaro N, Martella V, Lanave G, Varello K, et al.. Feline calicivirus infection in cats with virulent systemic disease, Italy.. Research in Veterinary Science. 2019. DOI: https://doi.org/10.1016/j.rvsc.2019.02.008

[4] Magliocca M, Mandrioli L, Battilani M, Bacci B, Ballotta G, Anjomanibenisi M, et al.. Description of a Virulent Systemic Feline Calicivirus Infection in a Kitten with Footpads Oedema and Fatal Pneumonia. Pathogens. 2025. DOI: https://doi.org/10.3390/pathogens14111183

[5] Duclos A, Ramos PJG, Mooney CT. Virulent systemic feline calicivirus infection: a case report and first description in Ireland. Irish Veterinary Journal. 2024. DOI: https://doi.org/10.1186/s13620-024-00262-3

[6] Deschamps J, Topie E, Roux F. Nosocomial feline calicivirus-associated virulent systemic disease in a veterinary emergency and critical care unit in France. JFMS open reports. 2015. DOI: https://doi.org/10.1177/2055116915621581

[7] Brunet S, Sigoillot-Claude C, Pialot D, Poulet H. Multiple Correspondence Analysis on Amino Acid Properties within the Variable Region of the Capsid Protein Shows Differences between Classical and Virulent Systemic Feline Calicivirus Strains. Viruses. 2019. DOI: https://doi.org/10.3390/v11121090

[8] Profio FD, Carnevale M, Marsilio F, Pellegrini F, Martella V, Martino BD, et al.. Feline Calicivirus Infection: Current Understanding and Implications for Control Strategies. Animals. 2025. DOI: https://doi.org/10.3390/ani15142009

[9] Karakaya-Bilen E, Akgül G, Yılmaz-Koç O. Suspected Feline Calicivirus Infection Triggering Ulcerative Oral and Skin Lesions in Cats Following Routine Ovariohysterectomy: A Postoperative Risk Assessment. Veterinary Medicine and Science. 2025. DOI: https://doi.org/10.1002/vms3.70540

[10] Wei Y, Zeng Q, Gou H, Bao S. Update on feline calicivirus: viral evolution, pathogenesis, epidemiology, prevention and control. Frontiers in Microbiology. 2024. DOI: https://doi.org/10.3389/fmicb.2024.1388420

[11] Battilani M, Vaccari F, Carelle MS, Morandi F, Benazzi C, Kipar A, et al.. Virulent feline calicivirus disease in a shelter in italy: A case description. Research in Veterinary Science. 2013. DOI: https://doi.org/10.1016/j.rvsc.2013.01.025

[12] Spiri A, Novacco M, Meli M, Stirn M, Riond B, Fogle J, et al.. Modified-Live Feline Calicivirus Vaccination Elicits Cellular Immunity against a Current Feline Calicivirus Field Strain in an Experimental Feline Challenge Study. Viruses. 2021. DOI: https://doi.org/10.3390/v13091736

[13] Spiri A, Riond B, Stirn M, Novacco M, Meli M, Boretti F, et al.. Modified-Live Feline Calicivirus Vaccination Reduces Viral RNA Loads, Duration of RNAemia, and the Severity of Clinical Signs after Heterologous Feline Calicivirus Challenge. Viruses. 2021. DOI: https://doi.org/10.3390/v13081505

[14] Acar G, Lge-Dagalp SB. Investigation of the epidemiology of calicivirus infection of cats using molecular and virus isolation techniques.. Comparative Immunology, Microbiology & Infectious Diseases. 2025. DOI: https://doi.org/10.1016/j.cimid.2025.102335

[15] Berger A, Willi B, Meli M, Boretti F, Hartnack S, Dreyfus A, et al.. Feline calicivirus and other respiratory pathogens in cats with Feline calicivirus-related symptoms and in clinically healthy cats in Switzerland. BMC Veterinary Research. 2015. DOI: https://doi.org/10.1186/s12917-015-0595-2

[16] Pedersen N, Elliott J, Glasgow A, Poland A, Keel K. An isolated epizootic of hemorrhagic-like fever in cats caused by a novel and highly virulent strain of feline calicivirus. Veterinary Microbiology. 2000. DOI: https://doi.org/10.1016/S0378-1135(00)00183-8

[17] Hofmann-Lehmann R, Hosie M, Hartmann K, Egberink H, Truyen U, Tasker S, et al.. Calicivirus Infection in Cats. Viruses. 2022. DOI: https://doi.org/10.3390/v14050937

[18] Heng W, Zang D, Li R, Qi R, Jiang Q, Liu J, et al.. A Virulent Systemic Feline Calicivirus Strain Isolated in China Could Produce Broadly Neutralizing Antibodies Against Multiple Strains. Transboundary and Emerging Diseases. 2025. DOI: https://doi.org/10.1155/tbed/6853477

[19] Guo H, Miao Q, Zhu J, Yang Z, Liu G. Isolation and molecular characterization of a virulent systemic feline calicivirus isolated in China.. Infection, Genetics and Evolution. 2018. DOI: https://doi.org/10.1016/j.meegid.2018.08.029

[20] Asif S, Deng Y, Meng C. Unlocking the secrets of Feline calicivirus: advances in structural and nonstructural proteins and its role as a key model for other Caliciviruses. Virology Journal. 2025. DOI: https://doi.org/10.1186/s12985-025-02750-6

[21] Luo D, Xie W, Li N, Peng X, Li K, Zhou X, et al.. Identification and Pathogenicity Analysis of Feline Calicivirus in Shanghai and Guangdong, China. Transboundary and Emerging Diseases. 2025. DOI: https://doi.org/10.1155/tbed/8729295

[22] Lee S, Kim Y, Kim Y, Na E, Kim Y, Oem J. Intergenic recombination in feline calicivirus associated with a hemorrhagic-like disease in the Republic of Korea.. Acta virologica. 2021. DOI: https://doi.org/10.4149/av_2021_206

[23] Kim S, Cheng Y, Fang Z, Liu X, Qiu Z, Yu W, et al.. Molecular epidemiology and phylogenetic analysis of feline calicivirus in Kunshan, China. Virology Journal. 2024. DOI: https://doi.org/10.1186/s12985-024-02319-9

[24] Liu X, Tao W, Yu Y, Yang H, Shan H, Zhang C. Genetic Characterization of Feline Calicivirus From China Reveals That Amino Acid Mutations at 441-443 in The ORF2 E Region Are Related to Pathogenicity. . 2021. DOI: https://doi.org/10.21203/rs.3.rs-1049525/v1

[25] Phongroop K. Genetic characterization and strain differentiation of feline Calicivirus among cat population in Thailand by high resolution melting analysis. . None. DOI: https://doi.org/10.58837/chula.the.2021.400

[26] Zabiegala A, Kim Y, Chang K. Differential induction of PD-L1 expression in cells infected with feline infectious peritonitis virus and feline enteric coronavirus.. Virology. 2025. DOI: https://doi.org/10.1016/j.virol.2025.110734

[27] Zhang Z, Li J, Zhang C, Bai X, Zhang T. Rapid Detection of Feline Calicivirus Using Lateral Flow Dipsticks Based on CRISPR/Cas13a System. Animals. 2024. DOI: https://doi.org/10.3390/ani14243663

[28] Palombieri A, Sarchese V, Giordano MV, Fruci P, Crisi P, Aste G, et al.. Detection and Characterization of Feline Calicivirus Associated with Paw and Mouth Disease. Animals. 2022. DOI: https://doi.org/10.3390/ani13010065

[29] Zhao J, Liang L, Zhang G, Li W, Li S, Cui S, et al.. Establishment and Application of a Taqman Reverse Transcriptase Quantitative Real Time Pcr Assay for Feline Calicivirus. . 2021. DOI: https://doi.org/10.21203/RS.3.RS-267291/V1

[30] Rong S, Floyd-Hawkins K, King V. Oral Administration Following Subcutaneous Administration of FCV Vaccines Enhances Vaccine Efficacy against Challenge of a Highly Virulent Vs Feline Calicivirus. World Journal of Vaccines. 2014. DOI: https://doi.org/10.4236/WJV.2014.42010

[31] Phongroop K, Rattanasrisomporn J, Piewbang C, Tangtrongsup S, Rungsipipat A, Techangamsuwan S. Molecular epidemiology and strain diversity of circulating feline Calicivirus in Thai cats. Frontiers in Veterinary Science. 2024. DOI: https://doi.org/10.3389/fvets.2024.1377327

[32] Abd-Eldaim M, Wilkes R, Thomas KV, Kennedy M. Development and validation of a TaqMan real-time reverse transcription-PCR for rapid detection of feline calicivirus. Archives of Virology. 2009. DOI: https://doi.org/10.1007/s00705-009-0337-5

[33] Fumian T, Tuipulotu DE, Netzler NE, Lun J, Russo AG, Yan GJH, et al.. Potential Therapeutic Agents for Feline Calicivirus Infection. Viruses. 2018. DOI: https://doi.org/10.3390/v10080433

[34] Li Z. An Integrated Review of Feline Calicivirus, Panleukopenia Virus, Herpesvirus, and Coronavirus: From Viral Entry to Disease Control. Theoretical and Natural Science. 2026. DOI: https://doi.org/10.54254/2753-8818/2026.32461

[35] Borsha RP, Hasan M, Zabbar MA, Khan MR, Zabed MA, Wasef A, et al.. Prevalence Assessment of Feline Infectious Peritonitis Based on Rapid Test and Protein Ratio Analysis in Dhaka, Bangladesh. Research in Agriculture, Livestock and Fisheries. 2025. DOI: https://doi.org/10.3329/ralf.v12i3.86115

[36] Pandya DK, Rao NM, Chauhan RA, Gelat MN, Parmar JN, Patel NJ. A Comprehensive Review of Ocular Manifestations Associated with Major Feline Viral Infections. bionature. 2025. DOI: https://doi.org/10.56557/bn/2025/v45i22083

[37] Usta M, Ayaz A, Kurban MY, Karaman M. Immune mechanisms in the pathogenesis of feline infectious peritonitis in renal tissue: Focus on lymphocytes and cytokines in effusive and non-effusive forms.. Research in Veterinary Science. 2026. DOI: https://doi.org/10.1016/j.rvsc.2026.106142

[38] удк, Т.И Г, О.В С, А.А Н, А.Г Г, Ю.В В, et al.. [Isolation and phylogenetic analysis of feline calicivirus in Siberia.]. Voprosy virusologii. 2018. DOI: https://doi.org/10.18821/0507-4088-2018-63-6-268-274

[39] Rudchenko A. Feline Calicivirosis in the catteries. Scientific Messenger of LNU of Veterinary Medicine and Biotechnologies. 2024. DOI: https://doi.org/10.32718/nvlvet11403

[40] Heng W, Zang D, Li R, Jiang Q, Liu J, Jia H, et al.. A novel replication-deficient FCV vaccine provides strong immune protection in cats. Journal of Virology. 2025. DOI: https://doi.org/10.1128/jvi.00093-25

[41] Wang X, Zhang D, Tang A, Zhang M, Zhu S, Zhu Y, et al.. Establishment of a reverse genetics system for virulent systemic feline calicivirus using circular polymerase extension reaction.. Journal of Virological Methods. 2024. DOI: https://doi.org/10.1016/j.jviromet.2024.115031

[42] Yan Y, Yang M, Jiao Y, Li L, Liu Z, Shi J, et al.. Drug screening identified that handelin inhibits feline calicivirus infection by inhibiting HSP70 expression in vitro.. Journal of General Virology. 2024. DOI: https://doi.org/10.1099/jgv.0.001936

[43] . Nitazoxanide protects cats from feline calicivirus infection and acts synergistically with mizoribine in vitro. Antiviral Research. 2020. DOI: https://doi.org/10.1016/j.antiviral.2020.104827

[44] Synowiec A, Pachota M, Krejmer-Rąbalska M, Ziemann D, Szczubiałka K, Jank M, et al.. Antiviral effect of poly(styrene 4-sulfonate) (PSSNa) on feline calicivirus oral infections in cats, field study. Veterinary Quarterly. 2026. DOI: https://doi.org/10.1080/01652176.2026.2616395

[45] Liu Z, Wu G, Mao J, Zheng Y, Fu Q, Lin S, et al.. Lapachol, a Dihydroorotate Dehydrogenase Inhibitor, Demonstrates Antiviral Activity against Feline Calicivirus in Vitro and in Vivo.. Antiviral Research. 2026. DOI: https://doi.org/10.1016/j.antiviral.2026.106354